InvestorsHub Logo
Followers 20
Posts 5367
Boards Moderated 0
Alias Born 01/04/2012

Re: None

Saturday, 02/25/2017 11:35:05 AM

Saturday, February 25, 2017 11:35:05 AM

Post# of 14942
Ani Pharmaceuticals paid approx. $51 million for Inderall XL and Innopran XL.

Yet they reported 16.155 Million in cash and cash equivalents in Q3 filing.

Q3

With a $30 million revolving credit facility that only gives them 46.155 million.

They appear $4.845 million short.

Either they had a very good 4th quarter or have additional cash coming in.

Next week could get very interesting.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ANIP News